News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
40,031 Results
Type
Article (1586)
Company Profile (7)
Press Release (38438)
Section
Business (16981)
Career Advice (9)
Deals (2435)
Drug Delivery (1)
Drug Development (4175)
Employer Resources (1)
FDA (616)
Job Trends (1023)
News (23228)
Policy (1302)
Tag
Academia (89)
Accelerated approval (1)
Adcomms (1)
Allergies (4)
Alliances (1399)
ALS (8)
Alzheimer's disease (60)
Antibody-drug conjugate (ADC) (2)
Approvals (638)
Artificial intelligence (12)
Bankruptcy (14)
Best Places to Work (1031)
Biosimilars (1)
Biotechnology (6)
Bladder cancer (15)
Breast cancer (30)
Cancer (203)
Cardiovascular disease (12)
Career advice (9)
CAR-T (9)
Cell therapy (22)
Clinical research (3620)
Collaboration (30)
Compensation (7)
COVID-19 (84)
CRISPR (1)
C-suite (2)
Cystic fibrosis (5)
Data (236)
Depression (1)
Diabetes (13)
Diagnostics (397)
Digital health (2)
Drug discovery (8)
Drug pricing (1)
Duchenne muscular dystrophy (6)
Earnings (14970)
Employer resources (1)
Events (6886)
Executive appointments (5)
FDA (751)
Funding (23)
Gene editing (2)
Generative AI (2)
Gene therapy (10)
GLP-1 (28)
Government (132)
Grass and pollen (2)
Guidances (57)
Healthcare (1082)
IgA nephropathy (1)
Immunology and inflammation (10)
Indications (4)
Infectious disease (90)
Inflammatory bowel disease (12)
Influenza (2)
Intellectual property (1)
IPO (1853)
IRA (1)
Job creations (57)
Job search strategy (9)
Layoffs (9)
Legal (162)
Liver cancer (3)
Lung cancer (28)
Lymphoma (19)
Manufacturing (7)
MASH (7)
Medical device (833)
Medtech (833)
Mergers & acquisitions (600)
Metabolic disorders (39)
Multiple sclerosis (2)
NASH (1)
Neurodegenerative disease (4)
Neuropsychiatric disorders (1)
Neuroscience (90)
NextGen: Class of 2025 (221)
Non-profit (81)
Obesity (20)
Opinion (1)
Ovarian cancer (3)
Pain (4)
Pancreatic cancer (7)
Parkinson's disease (5)
Patents (6)
Patient recruitment (3)
Peanut (1)
People (1114)
Phase I (887)
Phase II (1536)
Phase III (1530)
Pipeline (285)
Policy (3)
Postmarket research (124)
Preclinical (364)
Press Release (1)
Prostate cancer (11)
Psychedelics (3)
Radiopharmaceuticals (15)
Rare diseases (14)
Real estate (142)
Recruiting (1)
Regulatory (1121)
Reports (1)
Research institute (57)
RSV (2)
Schizophrenia (10)
Series A (2)
Series B (1)
Service/supplier (1)
Spinal muscular atrophy (5)
Startups (99)
Vaccines (25)
Venture capitalists (1)
Weight loss (9)
Date
Today (25)
Last 7 days (136)
Last 30 days (268)
Last 365 days (2526)
2025 (972)
2024 (2765)
2023 (3093)
2022 (4192)
2021 (3742)
2020 (2972)
2019 (2402)
2018 (1667)
2017 (1275)
2016 (985)
2015 (1420)
2014 (971)
2013 (605)
2012 (797)
2011 (832)
2010 (773)
Location
Africa (21)
Alabama (3)
Arizona (14)
Asia (2430)
Australia (270)
California (519)
Canada (154)
China (66)
Colorado (30)
Connecticut (25)
Delaware (16)
Europe (4876)
Florida (74)
Georgia (13)
Idaho (3)
Illinois (37)
India (1)
Indiana (31)
Japan (29)
Kansas (13)
Kentucky (1)
Louisiana (4)
Maine (10)
Maryland (63)
Massachusetts (344)
Michigan (20)
Minnesota (36)
Missouri (6)
Montana (3)
Nevada (5)
New Hampshire (5)
New Jersey (195)
New York (159)
North Carolina (85)
Northern California (256)
Ohio (13)
Pennsylvania (133)
South America (27)
Southern California (199)
Tennessee (3)
Texas (45)
United States (1924)
Utah (19)
Virginia (7)
Washington D.C. (3)
Washington State (43)
Wisconsin (7)
40,031 Results for "103".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
May 5, 2025
·
8 min read
Press Releases
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
April 25, 2025
·
4 min read
Press Releases
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease
April 4, 2025
·
3 min read
Press Releases
COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
February 4, 2025
·
3 min read
Press Releases
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
March 5, 2025
·
7 min read
Drug Development
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
CASI Pharmaceuticals, Inc. announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP).
May 15, 2024
·
5 min read
Drug Development
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
Dianthus Therapeutics, Inc. announced U.S. Food and Drug Administration clearance of its Phase 2 Investigational New Drug application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy.
June 12, 2024
·
6 min read
Press Releases
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
January 6, 2025
·
5 min read
Genetown
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.
June 28, 2024
·
6 min read
Ubix Therapeutics and Yuhan Announce Exclusive License Agreement for UBX-103, an Oral Small Molecule AR Degrader for Treatment of Metastatic Castration Resistant Prostate Cancer
Ubix Therapeutics, Inc., a biotechnology company discovering and developing innovative oncology therapeutics based on targeted protein degradation (TPD), announced today that it has entered into an exclusive license agreement with Yuhan to develop and commercialize preclinical androgen receptor (AR) degrader program, UBX-103.
July 1, 2024
·
2 min read
1 of 4,004
Next
